YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
According to Nixon’s lawsuits, the companies sold drugs to Medicaid providers and pharmacies for one price, and then reported a higher price to Medicaid for provider reimbursements. Nixon estimates the scheme cost Missouri taxpayers about $19 million since 1994.
In one instance, a drug used to treat heartburn was sold to a provider for about 7 cents per unit, but the price reported for reimbursement was more than $1.42 per unit.
“By reporting inflated prices that were then used to calculate Medicaid reimbursement, the companies were defrauding taxpayers in order to increase their market shares,” Nixon said in a news release.
The lawsuits are against Mylan Laboratories Inc. and its subsidiary Mylan Pharmaceuticals Inc.; Teva Pharmaceuticals USA Inc., its parent company Teva Pharmaceutical Industries Ltd. and Novopharm, a subsidiary of Teva Pharmaceutical Industries; Watson Pharmaceuticals Inc. and its subsidiary Watson Pharma Inc.; and Boehringer Ingelheim Roxane Inc., its parent company Boerhinger Ingelheim Corp. and four related corporations.
The drugs prescribed included antibiotics and those used to treat anxiety, heartburn and other ailments and diseases.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Banker pleads guilty to fraud scheme
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Caterpillar to acquire John Fabick Tractor Co.
Eric Schmitt introduces Modern Skies Act
Springfield airport to cut the ribbon on $35M in construction projects